null

Anti-Human CD194 (CCR4) (Mogamulizumab) - Biotin Biosimilar (IVMB0421)

SKU:
IVMB0421
€729

Description

system_update_altDatasheetsystem_update_altMSDS
Product Name:Anti-Human CD194 (CCR4) (Mogamulizumab) - Biotin
SKU:IVMB0421
Size:100 µg
Antibody Type:Biosimilar Recombinant Human Monoclonal Antibody
Clone:KW-0761
Target:CD194
Isotype:Human IgG1κ
Host Species:Human
Reactivity:Human
Applications:Depletion
Expression Host:HEK-293 Cells
FC Effector Activity:Active
Synonyms:Mogamulizumab, CD194, CCR4
Product Concentration:0.5 mg/ml
Immunogen:Humanization of mouse anti-CCR4 mAb7.
Applications and Recommended Usage:FC The suggested concentration for Mogamulizumab biosimilar antibody for staining cells in flow cytometry is ≤ 1.0 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application.
ELISA
Antigen Distribution:CCR4 is primarily expressed by Th2 and regulatory T cells in addition to expression on leukemic cells in cutaneous T-cell lymphoma (CTCL).
Formulation:This Biotinylated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Specificity:This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Mogamulizumab. Clone KW-0761 recognizes human CD194 (CCR4). This product is for research use only.
Additional Applications Reported In Literature:FA
Additional Reported Applications For Relevant Conjugates:Depletion

Clone KW-0761 (Mogamulizumab) is a research-grade, afucosylated, humanized monoclonal antibody generated from mouse anti-CCR4 mAb7 that targets human CCR4.1 CC chemokine receptor type 4 (CCR4) is a protein that belongs to the G protein-coupled receptor family and is a receptor for a variety of CC chemokines including MCP-1, MIP-1, RANTES, TARC, and Macrophage-derived chemokine. Chemokines are involved in the development, homeostasis, and function of the immune system and are known to regulate cell trafficking of various types of leukocytes. In a 2018 Phase I clinical trial, Mogamulizumab was found to decrease the number of HTLV-1–infected cells and the levels of inflammatory markers related to HTLV-1–Associated Myelopathy.3

Regulatory Status:Research Use Only (RUO). Non-Therapeutic.
Storage and Handling:Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
Research Area:Biosimilars

Related Products